Furthermore, bevacizumab, a monoclonal antibody against VEGF-A has demonstrated clinical efficacy in the treatment of a number of cancers, including melanoma, both as a stand-alone drug and in combination with chemotherapeutics like carboplatin and paclitaxel [173,174,175]. Here, VEGFA is linked to cancer.